Protagonist Therapeutics, Inc (PTGX) — Analysis Summary
Protagonist Therapeutics, Inc (PTGX) has a market cap of $9.56B with year-over-year revenue growth of -89.4%. Net margin stands at -282.8%. The stock trades at a P/E ratio of 115.3.
Key Takeaways
- Revenue changed -89.4% year-over-year
- Net margin of -282.8%
- P/E ratio of 115.3
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, PTGX posted revenue growth of -89.4% and trades at a P/E of 115.3.
Protagonist Therapeutics, Inc (PTGX)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsWatch List
Some caution signals are active and should be weighed alongside the valuation work.
Operating margin (20.7%) exceeds gross margin (0.0%) — check for other operating income or data classification issues
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
141
Headquarters
NEWARK, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.